Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis

Journal of Clinical Investigation

Volumn 109, Issue 5, 2002, Pages 603-611

  Sasaki, Ken Ichiro ^a   Murohara, Toyoaki ^a   Ikeda, Hisao ^a   Sugaya, Takeshi ^b   Shimada, Toshifumi ^a   Shintani, Satoshi ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; HYDRALAZINE; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL INFILTRATION; CELL TRANSPLANTATION; COLLATERAL CIRCULATION; CONTROLLED STUDY; DOSE RESPONSE; IMMUNOFLUORESCENCE; KNOCKOUT MOUSE; LIMB ISCHEMIA; MACROPHAGE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STRAIN DIFFERENCE; T LYMPHOCYTE; WILD TYPE;

EID: 0036199933     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0213055     Document Type: Article

References (50)

1. Essential hypertension: Rennin and aldosterone, heart attack and stroke
2. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
3. Angiogenesis in cancer, vascular, rheumatoid and other disease
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus
6. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats
7. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo
8. Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins
9. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia
10. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
11. Chymase as a proangiogenic factor. A possible involvement of chymaseangiotensin-dependent pathway in the hamster sponge angiogenesis model
12. Angiotensin II receptors and angiotensin II receptor antagonists
13. Angiotensin II type 1 receptor blockers
14. Balloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta
15. Vascular injury causes neointimal formation in angiotensin II type 1a receptor knockout mice
16. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia
17. Regulation of blood pressure by the type 1A angiotensin II receptor gene
18. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice
19. A mouse model of angiogenesis
20. Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: Nitric oxide-dependent mechanism
21. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury
22. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro
23. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction
24. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure
25. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats
26. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages
27. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway
28. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis
29. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo
30. Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats
31. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
32. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells
33. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells
34. Retinal neovascularization is prevented by blockade of the renin-angiotensin system
35. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells
36. Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure
37. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension
38. Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats
39. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo
40. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in apoE-/- mice
41. Age-dependent impairment of angiogenesis
42. Lack of hypoxic stimulation of VEGF secretion from neutrophils and platelets
43. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion
44. Time course of arteriogenesis following femoral artery occlusion in the rabbit
45. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization
46. Augmentation of postnatal neovascularization with autologous bone marrow transplantation
47. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers
48. Proposed update of angiotensin receptor nomenclature
49. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
50. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma